A detailed history of Centiva Capital, LP transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 22,160 shares of LYEL stock, worth $13,517. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,160
Holding current value
$13,517
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.13 - $1.88 $25,040 - $41,660
22,160 New
22,160 $30,000
Q3 2023

Nov 14, 2023

BUY
$1.45 - $3.35 $28,225 - $65,211
19,466 New
19,466 $28,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.